Phase 2 N=484 Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
Tularemia
Primary: Safety: Adverse Event Category Rates for All Vaccinations — 264; 162; 53; 48 Adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Mechanism of Action Study for Psoriasis
Psoriasis
Primary: Biologic Activity Endpoints — -3.85; -2.83; 0.05; 0.84 fold change — p=<0.05
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
N/A N=20 Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG
Post-Surgical Scars
Primary: Patient Observer Scar Assessment Scale (POSAS) — 17.69; 11.2; 15.2; 11.4 units on a scale — p=0.019
N/A N=18 Eplerenone for the Treatment of Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. — 139.3; 135.9; 51.8; 172.3 microns
Phase 2 N=49 Letrozole in Preventing Breast Cancer in Postmenopausal Women
Breast Cancer
Primary: Change in Lumbar Density From Baseline to 12 Months — -0.036; -0.021 g/cm^2 — p=0.15
Phase 2 N=25 The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
HIV-1 Infection
Primary: Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO — 8; 4 Participants
Phase 3 N=64 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan — 7275.1; 8535.4 h*ng/mL
Phase 3 N=314 Staccato Loxapine in Agitated Patients With Bipolar Disorder
Bipolar I Disorder
Primary: Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo — -4.9; -8.1; -9.0 units on a scale — p=<0.0001
Phase 2 N=8 Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
Non-melanoma Skin Cancer
Primary: The Primary Efficacy Measure Was the Investigator's Global Assessment of Healing (IGAH). — 2.75; 2.25; 3.00; 3.00 units on a scale — p=0.263
Phase 2 N=250 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Crohn's Disease
Primary: Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) — 55; 58 Participants
Phase 4 N=308 Testosterone Replacement in Older Men and Atherosclerosis Progression
Hypogonadism · Atherosclerosis
Primary: Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT) — 0.877; 0.879; 0.036; 0.033 mm
Phase 4 N=34 Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments
Post-traumatic Stress Disorder
Primary: Physiological Posttraumatic Stress Disorder (PTSD) Probability as Determined From Psychophysiologic Responses to Traumatic Recollection — 44; 45 percent probability
N/A N=66 Geriatric Patients and Laryngeal Mask Unique
Anaesthesia
Primary: Number of Participants With Successful Laryngeal Mask Placement — 26; 20; 6; 11 Participants
N/A N=80 Knee Bracing for People With Patellofemoral Osteoarthritis
Knee Osteoarthritis
Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline